Today: 1 May 2026
Rocket Companies stock (RKT) jumps on Trump’s $200B mortgage-bond move — what to watch next
11 January 2026
2 mins read

Rocket Companies stock (RKT) jumps on Trump’s $200B mortgage-bond move — what to watch next

NEW YORK, Jan 10, 2026, 18:43 ET — Market closed.

  • Rocket Companies jumped 9.6% Friday, lifted by a surge in housing stocks after the U.S. unveiled a fresh mortgage-bond buying program
  • The Trump administration directed $200 billion worth of mortgage-backed securities purchases linked to Fannie Mae and Freddie Mac
  • Traders are focused on mortgage rates, the next steps in policy, and Tuesday’s U.S. inflation report

Shares of Rocket Companies, Inc soared 9.6% on Friday, closing at $23.29 after hitting an intraday high of $23.41. Investors rushed into mortgage lenders following new signs that Washington aims to push home-loan rates down.

This matters because Rocket’s main operation—originating home loans via Rocket Mortgage—often shifts with interest rates. When borrowing costs drop, refinancing and buying activity generally rise, sparking competition among lenders for volume.

The sensitivity has resurfaced amid renewed pressure from policymakers on housing affordability. Although mortgage rates have dropped from their peaks last year, they remain far above the pandemic-era lows, leaving many borrowers hesitant to jump in.

Rocket’s shares jumped after a surge in U.S. mortgage lenders and housing-related stocks, following President Donald Trump’s announcement of $200 billion in mortgage-bond buys to lower housing costs. “Every little bit will help push mortgage yields lower,” noted Brian Jacobsen, chief economic strategist at Annex Wealth Management, though he cautioned this move might also boost demand. Reuters

Treasury Secretary Scott Bessent told Reuters the plan is to keep pace with the Federal Reserve’s runoff of mortgage-backed securities, which runs around $15 billion a month, instead of flooding the market all at once. FHFA Director William Pulte confirmed an initial $3 billion tranche has kicked off. Mortgage-backed securities are bonds secured by pools of home loans.

Jefferies analysts said mortgage rates might have to drop to the mid- to high-5% range from roughly 6.2% before affordability improves enough to lure buyers back—a threshold the market hasn’t reached so far.

Policy headlines boosted Rocket’s publicly traded rivals like loanDepot and UWM Holdings, with gains extending to homebuilders and credit bureaus connected to lending.

That said, a headline order doesn’t automatically translate to a lasting drop in mortgage rates. Bessent noted the purchases probably won’t drive rates down directly. Instead, investors could soon shift their attention back to spreads, supply levels, and whether demand picks up again amid tight inventories.

The plan also raised doubts about the future of Fannie Mae and Freddie Mac, still under government control. TD Cowen’s Jaret Seiberg noted that Trump’s wording “does not sound like a President who is in a rush to IPO the enterprises,” complicating bets on a straightforward privatization. Reuters

Traders in Rocket stock will be keeping an eye on whether Friday’s price stays above the session low around $22, with the recent peak at about $23.41 serving as the next key level.

Next on the docket: inflation data that could shake things up. The U.S. Consumer Price Index for December 2025 drops Tuesday, Jan. 13, at 8:30 a.m. ET. This report often shifts rate expectations and could rattle mortgage stocks like Rocket.

Stock Market Today

  • Seaport Therapeutics Upsizes IPO to $255M, CEO Highlights New Biotech Pathway
    May 1, 2026, 2:02 PM EDT. Seaport Therapeutics raised $254.9 million in an upsized Nasdaq IPO, exceeding initial $180 million estimates. CEO Daphne Zohar highlighted a shift from traditional M&A (mergers and acquisitions) to public offerings, reflecting confidence in developing and marketing their depression drug pipeline independently. The company may raise an additional $38.2 million through underwriters' option. Zohar pointed to industry changes where biotech firms are now focusing on advancing medicines directly to patients, citing success stories like Karuna Therapeutics and Intra-Cellular Therapies. Seaport's board recently welcomed Sharon Mates, who led Intra-Cellular to a $1.5 billion drug launch before its J&J acquisition. This IPO signals renewals in the biotech public market despite recent Big Pharma dealmaking.

Latest article

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

1 May 2026
The Dow Jones Industrial Average fell 78.72 points to 49,573.42 by midday Friday, reversing an early rally as tariff concerns weighed on gains from Apple and other strong earnings reports. President Donald Trump announced a 25% tariff on EU-made cars and trucks starting next week. Apple reported quarterly revenue of $111.2 billion, up 17% year over year. Oil prices dropped after Iran sent a new negotiation proposal.
US Stock Market Today: Why the S&P 500 and Nasdaq Are Hitting Fresh Highs

US Stock Market Today: Why the S&P 500 and Nasdaq Are Hitting Fresh Highs

1 May 2026
The S&P 500 rose 0.48% and the Nasdaq 0.96% to record highs Friday, while the Dow slipped 0.11%. Apple shares climbed after reporting its strongest quarterly sales growth in over four years. Atlassian and other software stocks rallied on strong cloud demand. Exxon and Chevron beat profit estimates but cited pressure from Middle East conflict and volatile oil prices.
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

1 May 2026
Recursion Pharmaceuticals said founder and board chair Chris Gibson will not seek re-election at the June 17 annual meeting, months after stepping down as CEO. The company reports first-quarter results May 6, with investors watching for updates on cash, clinical progress, and its AI drug platform. Recursion last reported $753.9 million in cash and narrowed its quarterly net loss. Gibson will remain chair until his term ends.
Ford stock pulls back from rally as ‘eyes-off’ driving plan and Piper upgrade hit tape
Previous Story

Ford stock pulls back from rally as ‘eyes-off’ driving plan and Piper upgrade hit tape

NuScale Power stock jumps on BofA upgrade as Meta nuclear deals set up the week ahead
Next Story

NuScale Power stock jumps on BofA upgrade as Meta nuclear deals set up the week ahead

Go toTop